686 related articles for article (PubMed ID: 8387385)
41. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
42. Biochemical and pharmacological characterization of cyclic nucleotide phosphodiesterase in airway epithelium.
Rousseau E; Gagnon J; Lugnier C
Mol Cell Biochem; 1994 Nov; 140(2):171-5. PubMed ID: 7898488
[TBL] [Abstract][Full Text] [Related]
43. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.
Dent G; Giembycz MA; Evans PM; Rabe KF; Barnes PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422
[TBL] [Abstract][Full Text] [Related]
44. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
45. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine.
Podzuweit T; Nennstiel P; Müller A
Cell Signal; 1995 Sep; 7(7):733-8. PubMed ID: 8519602
[TBL] [Abstract][Full Text] [Related]
46. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors.
Reeves ML; Leigh BK; England PJ
Biochem J; 1987 Jan; 241(2):535-41. PubMed ID: 3036066
[TBL] [Abstract][Full Text] [Related]
47. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.
Komas N; Lugnier C; Stoclet JC
Br J Pharmacol; 1991 Oct; 104(2):495-503. PubMed ID: 1665741
[TBL] [Abstract][Full Text] [Related]
48. Subclasses of cyclic AMP phosphodiesterase in cardiac muscle.
Weishaar RE; Kobylarz-Singer DC; Kaplan HR
J Mol Cell Cardiol; 1987 Oct; 19(10):1025-36. PubMed ID: 2830402
[TBL] [Abstract][Full Text] [Related]
49. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.
Hatzelmann A; Tenor H; Schudt C
Br J Pharmacol; 1995 Feb; 114(4):821-31. PubMed ID: 7539697
[TBL] [Abstract][Full Text] [Related]
50. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
51. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
Ahn HS; Eardley D; Watkins R; Prioli N
Biochem Pharmacol; 1986 Apr; 35(7):1113-21. PubMed ID: 2421728
[TBL] [Abstract][Full Text] [Related]
52. Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11.
Ahmad M; Abdel-Wahab YH; Tate R; Flatt PR; Pyne NJ; Furman BL
Br J Pharmacol; 2000 Mar; 129(6):1228-34. PubMed ID: 10725272
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
Ilien B; Ruckstuhl M; Landry Y
J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
[TBL] [Abstract][Full Text] [Related]
54. Involvement of cyclic AMP generation in the inhibition of respiratory burst by 2-phenyl-4-quinolone (YT-1) in rat neutrophils.
Wang JP; Raung SL; Huang LJ; Kuo SC
Biochem Pharmacol; 1998 Dec; 56(11):1505-14. PubMed ID: 9827585
[TBL] [Abstract][Full Text] [Related]
55. Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles.
Muller B; Stoclet JC; Lugnier C
Eur J Pharmacol; 1992 Mar; 225(3):263-72. PubMed ID: 1325367
[TBL] [Abstract][Full Text] [Related]
56. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
57. Isolation and characterization of the rolipram-sensitive cyclic AMP-specific phosphodiesterase (type IV PDE) in human term myometrium.
Leroy MJ; Lugnier C; Merezak J; Tanguy G; Olivier S; Le Bec A; Ferré F
Cell Signal; 1994 May; 6(4):405-12. PubMed ID: 7946965
[TBL] [Abstract][Full Text] [Related]
58. Selective inhibition of cyclic AMP and cyclic GMP phosphodiesterases of cardiac nuclear fraction.
Ahluwalia GS; Rhoads AR
Biochem Pharmacol; 1982 Mar; 31(5):665-9. PubMed ID: 6177320
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of phosphodiesterase IV and intracellular calcium levels in human polymorphonuclear leukocytes.
Villagrasa V; Navarrete C; Sanz C; Berto L; Perpiñá M; Cortijo J; Morcillo EJ
Methods Find Exp Clin Pharmacol; 1996 May; 18(4):239-45. PubMed ID: 8803956
[TBL] [Abstract][Full Text] [Related]
60. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
